Boundless Bio Inc (BOLD) Stock Price, Quote & News

Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor s...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 766 9912

Website: boundlessbio.com

Address:

10955 Alexandria Way, Suite 100, San Diego, United States

gata2016 May. 8 at 3:25 PM

$AUPH This post may have been sarcastic? I was referring to $BOLD currently trading at 1.50. I had just tagged AUPH and a couple others as these are my main BIO portfolio.

1 · Reply

gata2016 May. 8 at 2:32 PM

$ALLR Zack's price target = 9.75. I'll HLD for that. $BOLD $AUPH $SLS

0 · Reply

gata2016 May. 8 at 12:23 PM

$ALLR Stairway looking nice here. Waiting on $BOLD to get it's act together, but still very early on. $AUPH WAY overreacted on news yesterday. If anything news was positive. Strong balance sheet, buy backs, and signs of a potential BO coming very soon (Mgt released and building lease will not be renewed). $AUPH $FATE $SLS

0 · Reply

focafoca99 May. 8 at 12:08 PM

$BOLD released its financial results for the quarter ended March 31, 2026.

0 · Reply

55X_ROI_Q1_2026 May. 7 at 7:26 PM

$SLS $AUPH we are beginning to see the SLS Buyout Articles. $BOLD $ALLR

0 · Reply

gata2016 May. 7 at 7:12 PM

$AUPH May not close green, but we are heading back. Sounds like there is some potential big news brewing. Shocked for the selloff when there seems to be something big coming. $BOLD $ALLR $SLS

1 · Reply

gata2016 May. 7 at 4:13 PM

$BOLD Added a starter position here. This is extremely cheap for the market they are in. $ALLR $AUPH $SLS

1 · Reply

SuperGreenToday May. 6 at 6:55 PM

$BOLD

0 · Reply

gata2016 May. 5 at 6:09 PM

$BOLD I see there was supposed to be a conference recently. Does BOLD not do PRs before/after, or share any data about the therapy? I dont see anything on this board with info about what they are doing.

0 · Reply

gata2016 May. 5 at 6:06 PM

$BOLD Whew, this wasnt a good move.

0 · Reply

Boundless Bio reports Q1 EPS (60c), consensus (56c)

May 8, 2026, 7:00 AM EDT - 2 days ago

Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights

2026-04-17T21:00:47.000Z - 23 days ago

Boundless Bio presents preclinical data for BBI-940 therapy at AACR

Apr 17, 2026, 4:49 PM EDT - 23 days ago

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Mar 17, 2026, 4:52 PM EDT - 7 weeks ago

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Mar 11, 2026, 11:20 AM EDT - 2 months ago

Boundless Bio Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T11:06:35.000Z - 2 months ago

Boundless Bio reports Q4 EPS (58c), consensus (52c)

2026-03-09T11:06:21.000Z - 2 months ago

Boundless Bio sees cash runway into 2H28

Mar 9, 2026, 7:00 AM EDT - 2 months ago

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 4, 2026, 7:00 AM EST - 2 months ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Feb 12, 2026, 3:00 PM EST - 3 months ago

Boundless Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 3 months ago

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-20T12:16:02.000Z - 3 months ago

Boundless Bio announces FDA accepted IND application of BBI-940

2026-01-20T12:15:45.000Z - 3 months ago

Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825

Jan 20, 2026, 7:00 AM EST - 3 months ago

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Dec 3, 2025, 9:30 AM EST - 5 months ago

Boundless Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 5 months ago

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

2025-11-05T12:06:32.000Z - 6 months ago

Boundless Bio reports Q3 EPS (62c), consensus (58c)

2025-11-05T12:05:53.000Z - 6 months ago

Boundless Bio sees cash runway into 1H28

Nov 5, 2025, 7:00 AM EST - 6 months ago

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 13, 2025, 4:05 PM EDT - 7 months ago

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-08-11T10:15:45.000Z - 9 months ago

Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright

2025-08-05T11:13:07.000Z - 9 months ago

Boundless Bio reports Q2 EPS (70c), consensus (65c)

Aug 5, 2025, 7:00 AM EDT - 9 months ago

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

2025-07-24T20:55:16.000Z - 10 months ago

Boundless Bio initiated with Early-Stage Biotech at Goldman Sachs

Jun 9, 2025, 9:20 AM EDT - 11 months ago

Boundless Bio Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 5, 2025, 4:58 PM EDT - 1 year ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

2025-06-02T10:15:17.000Z - 1 year ago

Boundless Bio initiated with a Buy at H.C. Wainwright

2025-05-27T20:40:07.000Z - 1 year ago

Boundless Bio downgraded to Market Perform from Outperform at Leerink

May 27, 2025, 8:00 AM EDT - 1 year ago

Boundless Bio Transcript: Status Update

2025-05-23T20:05:14.000Z - 1 year ago

Boundless Bio discontinuing BBI-355 and BBI-825 programs

May 23, 2025, 4:01 PM EDT - 1 year ago

Boundless Bio Announces Portfolio Prioritization and Runway Extension

2025-05-09T11:14:02.000Z - 1 year ago

Boundless Bio reports Q1 EPS (71c) vs ($12.27) last year

May 9, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Apr 3, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

2025-04-01T20:05:11.000Z - 1 year ago

Boundless Bio files $400M mixed securities shelf

2025-03-27T11:07:19.000Z - 1 year ago

Boundless Bio reports Q4 EPS (74c) vs ($9.76) last year

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 12, 2025, 11:20 AM EDT - 1 year ago

Boundless Bio Transcript: Leerink Global Healthcare Conference 2025

Feb 26, 2025, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

2025-02-03T15:05:25.000Z - 1 year ago

Boundless Bio appoints Robert Doebele as CMO

Feb 3, 2025, 10:00 AM EST - 1 year ago

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

2024-12-13T14:05:18.000Z - 1 year ago

Boundless Bio downgraded to Neutral at Guggenheim after BBI-825 scrapped

2024-12-13T11:20:57.000Z - 1 year ago

Boundless Bio downgraded to Neutral from Buy at Guggenheim

Dec 12, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Announces Pipeline and Leadership Updates

Dec 4, 2024, 3:30 PM EST - 1 year ago

Boundless Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Nov 12, 2024, 2:30 PM EST - 1 year ago

Boundless Bio Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 7, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Sep 18, 2024, 10:20 AM EDT - 1 year ago

Boundless Bio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Jun 12, 2024, 3:20 PM EDT - 2 years ago

Boundless Bio Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 13, 2024, 1:00 PM EDT - 2 years ago

Boundless Bio Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

May 6, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Mar 27, 2024, 6:55 PM EDT - 2 years ago

Boundless Bio Announces Pricing of Initial Public Offering

gata2016 May. 8 at 3:25 PM

$AUPH This post may have been sarcastic? I was referring to $BOLD currently trading at 1.50. I had just tagged AUPH and a couple others as these are my main BIO portfolio.

1 · Reply

gata2016 May. 8 at 2:32 PM

$ALLR Zack's price target = 9.75. I'll HLD for that. $BOLD $AUPH $SLS

0 · Reply

gata2016 May. 8 at 12:23 PM

0 · Reply

focafoca99 May. 8 at 12:08 PM

$BOLD released its financial results for the quarter ended March 31, 2026.

0 · Reply

55X_ROI_Q1_2026 May. 7 at 7:26 PM

$SLS $AUPH we are beginning to see the SLS Buyout Articles. $BOLD $ALLR

0 · Reply

gata2016 May. 7 at 7:12 PM

$AUPH May not close green, but we are heading back. Sounds like there is some potential big news brewing. Shocked for the selloff when there seems to be something big coming. $BOLD $ALLR $SLS

1 · Reply

gata2016 May. 7 at 4:13 PM

$BOLD Added a starter position here. This is extremely cheap for the market they are in. $ALLR $AUPH $SLS

1 · Reply

SuperGreenToday May. 6 at 6:55 PM

$BOLD

0 · Reply

gata2016 May. 5 at 6:09 PM

0 · Reply

gata2016 May. 5 at 6:06 PM

$BOLD Whew, this wasnt a good move.

0 · Reply

revuelto Apr. 28 at 12:09 PM

$BOLD extremely cheap…it is what it is 🤷‍♂️😀

0 · Reply

AlphaBull_10M Apr. 24 at 4:58 PM

$OKLO The Bull Case - AI Power Play $SOXL $BOLD $TQQQ

1 · Reply

AlphaBull_10M Apr. 24 at 12:42 PM

$INTC 2x leverage $INTW is up cool 50%, kind of spike that forever decaying $SOXS $BOLD $UVIX traders dream of.

0 · Reply

AlphaBull_10M Apr. 24 at 1:55 AM

$BOLD $KOLD $KORU $UVIX $BTC

0 · Reply

vu_jade Apr. 22 at 2:04 PM

$BOLD nice consolidation

0 · Reply

focafoca99 Apr. 17 at 8:54 PM

$BOLD Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting https://www.rapidticker.com/news/bold-boundless-bio-presents-preclinical-breast-8da716

0 · Reply

uptrend2025 Apr. 17 at 7:16 PM

$BOLD Cancer presentation this weekend 👀

0 · Reply

Golibajje Apr. 15 at 10:57 PM

$BOLD Along with this $BOLT is another lottery ticket in the making! It is trading nearly 1/4th of cash (low float with 1.9m shares.. $9M mkt cap vs $31M cash).. they have phase 1 results in Q3.. disruptive treatment in BILLION $$ mkt! Could go 500%+ if the results are positive! $ZNTL $ALMS

1 · Reply

Golibajje Apr. 15 at 3:54 PM

$BOLD breakout in 2-3 days!!

0 · Reply

revuelto Apr. 14 at 9:20 PM

$BOLD = GOLD 🎉

0 · Reply

vu_jade Apr. 14 at 7:52 PM

$BOLD & the beautiful Everyone will saybthey bought at $1 We have receipts .. See you at $5, $8, $10 & $16

1 · Reply

revuelto Apr. 14 at 6:21 PM

$BOLD there’s a reason for that 5.5m volume..welcome to the la la land soon 🎉

0 · Reply

Market Cap	32.28M
Revenue (ttm)	0.00
Net Income (ttm)	-58.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	399,700
Avg Vol	235,412
Day's Range	N/A - N/A
Shares Out	22.42M
Stochastic %K	13%
Beta	0.57
Analysts	Hold
Price Target	$4.00